3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Breast Neoplasms
2
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thrombocytosis
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
pembrolizumab
4
Nivolumab
3
Itraconazole
2
tucatinib
1
tremelimumab
1
regorafenib
1
pertuzumab
1
lenvatinib
1
larotrectinib
1
durvalumab
1
cemiplimab
1
brigimadlin
1
aflibercept
1
Trastuzumab
1
Ritonavir
1
Paclitaxel
1
Fulvestrant
1
Clinical Trials, Phase II as Topic
1
Carboplatin
1
Capecitabine
1
Antibodies
1
AZD9833
1
AZD5305
1
AZD 6244
1
ARX788
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
regorafenib
×
Breast
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled